Arginine Adjunctive Therapy in Active Tuberculosis

Farazi, Aliasghar; Shafaat, Omid; Sofian, Masoomeh; Kahbazi, Manijeh

doi:10.1155/2015/205016

Cited by 14 publications

(20 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One trial was stopped early when antiretrovirals became locally available (Semba 2007 MWI). Eleven trials excluded people with HIV infection (Hanekom 1997 ZAF; Paton 2004 SGP; Pérez-Guzmán 2005 MEX; Nursyam 2006 IDN; Armijos 2010 MEX; Jahnavi 2010 IND; Paliliewu 2013 IDN; Lodha 2014 IND; Daley 2015 IND; Farazi 2015 IRN; Mily 2015 BGD), and eight trials did not mention HIV infection (Morcos 1998 EGY; Karyadi 2002 IDN; Seyedrezazadeh 2006 IRN; Martins 2009 TLS; Pakasi 2010 IDN; Kota 2011 IND; Ginawi 2013 IND; Singh 2013 IND). …”

Section: Resultsmentioning

confidence: 99%

“…Asia: Singapore (Paton 2004 SGP), Indonesia (Karyadi 2002 IDN; Nursyam 2006 IDN; Pakasi 2010 IDN; Paliliewu 2013 IDN; Ralph 2013 IDN), Iran (Seyedrezazadeh 2006 IRN; Farazi 2015 IRN), Bangladesh (Mily 2015 BGD), and India (Jahnavi 2010 IND; Sudarsanam 2010 IND; Kota 2011 IND; Ginawi 2013 IND; Singh 2013 IND; Lodha 2014 IND; Daley 2015 IND). …”

Section: Resultsmentioning

confidence: 99%

“…Twenty-four trials described an adequate method of generating a truly random allocation sequence (Karyadi 2002 IDN; Schön 2003 ETH; Paton 2004 SGP; Range 2005 TZA; Semba 2007 MWI; Villamor 2008 TZA; Wejse 2008 GNB; Martins 2009 TLS; Lawson 2010 NGA; Pakasi 2010 IDN; Sudarsanam 2010 IND; Martineau 2011 GBR; Mehta 2011 TZA; Praygod 2011a TZA; Praygod 2011b TZA; Schön 2011 ETH; Visser 2011 ZAF; Ralph 2013 IDN; Jeremiah 2014 TZA; Lodha 2014 IND; Daley 2015 IND; Farazi 2015 IRN; Mily 2015 BGD; Tukvadze 2015 GEO). The other trials did not report how the random sequences were generated although all were described as "randomized".…”

Section: Resultsmentioning

confidence: 99%

“…Although treatment outcomes in tuberculosis such as cure, and treatment completion are well established in tuberculosis programmes only one trial reported cure (Sudarsanam 2010 IND), and five reported treatment completion (Martins 2009 TLS; Jahnavi 2010 IND; Pakasi 2010 IDN; Sudarsanam 2010 IND; Farazi 2015 IRN). We were unable to retrieve trial protocols.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Nutritional supplements for people being treated for active tuberculosis

Grobler

Nagpal

Sudarsanam

et al. 2016

Cochrane Database of Systematic Reviews

160

117

View full text Add to dashboard Cite

Background Tuberculosis and malnutrition are linked in a complex relationship. Tuberculosis may cause undernutrition through increased metabolic demands and decreased intake, and nutritional deficiencies may worsen the disease, or delay recovery by depressing important immune functions. At present, there is no evidence‐based nutritional guidance for adults and children being treated for tuberculosis. Objectives To assess the effects of oral nutritional supplements in people being treated with antituberculous drug therapy for active tuberculosis. Search methods We searched the Cochrane Infectious Disease Group Specialized Register, Cochrane Central Register of Controlled Trials (CENTRAL; Issue 1, 2016), MEDLINE (from 1946 to 4 February 2016), EMBASE (from 1980 to 4 February 2016), LILACS (from 1982 to 4 February 2016), the meta Register of Controlled Trials ( m RCT), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), and the Indian Journal of Tuberculosis up to 4 February 2016, and checked the reference lists of all included studies. Selection criteria Randomized controlled trials that compared any oral nutritional supplement given for at least four weeks with no nutritional intervention, placebo, or dietary advice only for people being treated for active tuberculosis. The primary outcomes of interest were all‐cause death, and cure at six and 12 months. Data collection and analysis Two review authors independently selected trials for inclusion, and extracted data and assessed the risk of bias in the included trials. We presented the results as risk ratios (RR) for dichotomous variables, and mean differences (MD) for continuous variables, with 95% confidence intervals (CIs). Where appropriate, we pooled data from trials with similar interventions and outcomes. We assessed the quality of the evidence using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Main results Thirty‐five trials, including 8283 participants, met the inclusion criteria of this review. Macronutrient supplementation Six trials assessed the provision of free food, or high‐energy supplements. Only two trials measured total dietary intake, and in both trials the intervention increased calorie consumption compared to controls. The available trials were too small to reliably prove or exclude clinically important benefits on mortality (RR 0.34, 95% CI 0.10 to 1.20; four trials, 567 participants, very low quality evidence ), cure (RR 0.91, 95% CI 0.59 to 1.41; one trial, 102 participants, very low quality evidence ), or treatment completion (data not pooled; two trials, 365 participants, very low quality evi...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Nutritional supplements for people being treated for active tuberculosis

Grobler

Nagpal

Sudarsanam

et al. 2016

Cochrane Database of Systematic Reviews

160

117

View full text Add to dashboard Cite

show abstract

“…Support for smoking cessation should be considered to improve outcomes in TB control programs (25). Arginine is useful as an adjunctive therapy in patients with active TB, in which the effects are more likely mediated by the increased production of nitric oxide and improved constitutional symptoms and weight gain (26).…”

Section: Discussionmentioning

confidence: 99%

The Follow-up of 360 Patients with Pulmonary Tuberculosis After 2 Months Treatment With Anti-tubercular Agents in Iran

Kazerani

Ashrafzadeh

et al. 2017

Arch Clin Infect Dis

View full text Add to dashboard Cite

Background: Tuberculosis (TB) is a major global health problem. The goal is to end the global TB epidemic. TB treatment averted 49 million deaths globally from 2000 to 2015. If everyone with TB had a timely diagnosis and high-quality treatment, the TB case fatality rate would be lower in all countries. The main source of infection is untreated smear positive pulmonary TB; the next step should be the examination of the sputum for Mycobacterium sp. Bacteriologic evaluation through culture and /smear microscopy is essential to monitor the response to treatment. Monitoring acid-fast bacilli (AFB) smear should be undertaken at 2, 5, and 6 months. The currently recommended treatment for the new cases of drug-susceptible TB is a 6-month regimen of 4 first-line drugs: isoniazid (INH), rifampin (RIF), ethambutol (ETM), and pyrazinamide (PZA). Treatment success rates of at least 85% for new cases of drugsusceptible TB are regularly reported to the world health organization (WHO) by its 194 member states. The global TB drug facility supplies a complete 6-month course for about US$ 40 per person.

show abstract